Sino Biopharmaceutical Limited (F:SMZ1) — Market Cap & Net Worth
Market Cap & Net Worth: Sino Biopharmaceutical Limited (SMZ1)
Sino Biopharmaceutical Limited (F:SMZ1) has a market capitalization of $13.26 Billion (€11.34 Billion) as of April 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #1629 globally and #267 in its home market, demonstrating a -1.43% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Sino Biopharmaceutical Limited's stock price €0.63 by its total outstanding shares 17885721987 (17.89 Billion).
Sino Biopharmaceutical Limited Market Cap History: 2015 to 2026
Sino Biopharmaceutical Limited's market capitalization history from 2015 to 2026. Data shows growth from $2.68 Billion to $13.26 Billion (17.34% CAGR).
Sino Biopharmaceutical Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Sino Biopharmaceutical Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.29x
Sino Biopharmaceutical Limited's market cap is 0.29 times its annual revenue
Latest Price to Earnings (P/E) Ratio
2.37x
Sino Biopharmaceutical Limited's market cap is 2.37 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $2.68 Billion | $14.55 Billion | $1.78 Billion | 0.18x | 1.51x |
| 2016 | $2.45 Billion | $14.17 Billion | $1.71 Billion | 0.17x | 1.43x |
| 2017 | $5.90 Billion | $14.82 Billion | $2.17 Billion | 0.40x | 2.72x |
| 2018 | $3.64 Billion | $20.89 Billion | $9.05 Billion | 0.17x | 0.40x |
| 2019 | $8.41 Billion | $24.23 Billion | $2.71 Billion | 0.35x | 3.11x |
| 2020 | $8.46 Billion | $23.65 Billion | $2.77 Billion | 0.36x | 3.05x |
| 2021 | $6.86 Billion | $26.86 Billion | $14.61 Billion | 0.26x | 0.47x |
| 2022 | $7.73 Billion | $26.03 Billion | $2.54 Billion | 0.30x | 3.04x |
| 2023 | $6.93 Billion | $26.20 Billion | $2.33 Billion | 0.26x | 2.97x |
| 2024 | $8.29 Billion | $28.87 Billion | $3.50 Billion | 0.29x | 2.37x |
Competitor Companies of SMZ1 by Market Capitalization
Companies near Sino Biopharmaceutical Limited in the global market cap rankings as of April 19, 2026.
Key companies related to Sino Biopharmaceutical Limited by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #184 globally with a market cap of $111.94 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #294 globally with a market cap of $77.99 Billion USD.
- UCB SA (BR:UCB): Ranked #454 globally with a market cap of $51.74 Billion USD ( €44.26 Billion EUR).
- argenx SE (SA:A1RG34): Ranked #455 globally with a market cap of $51.73 Billion USD ( R$263.66 Billion BRL).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #184 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $111.94 Billion | $441.20 |
| #294 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $77.99 Billion | $750.57 |
| #454 | UCB SA | BR:UCB | $51.74 Billion | €263.90 |
| #455 | argenx SE | SA:A1RG34 | $51.73 Billion | R$169.59 |
Sino Biopharmaceutical Limited Historical Marketcap From 2015 to 2026
Between 2015 and today, Sino Biopharmaceutical Limited's market cap moved from $2.68 Billion to $ 13.26 Billion, with a yearly change of 17.34%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €13.26 Billion | -6.63% |
| 2025 | €14.20 Billion | +71.21% |
| 2024 | €8.29 Billion | +19.67% |
| 2023 | €6.93 Billion | -10.41% |
| 2022 | €7.73 Billion | +12.74% |
| 2021 | €6.86 Billion | -18.89% |
| 2020 | €8.46 Billion | +0.55% |
| 2019 | €8.41 Billion | +131.07% |
| 2018 | €3.64 Billion | -38.33% |
| 2017 | €5.90 Billion | +140.87% |
| 2016 | €2.45 Billion | -8.58% |
| 2015 | €2.68 Billion | -- |
End of Day Market Cap According to Different Sources
On Apr 19th, 2026 the market cap of Sino Biopharmaceutical Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $13.26 Billion USD |
| MoneyControl | $13.26 Billion USD |
| MarketWatch | $13.26 Billion USD |
| marketcap.company | $13.26 Billion USD |
| Reuters | $13.26 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Sino Biopharmaceutical Limited
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injecti… Read more